Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

4 terminated/withdrawn out of 16 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

75%

6 of 8 completed trials have results

Key Signals

4 recruiting6 with results

Enrollment Performance

Analytics

Phase 2
14(87.5%)
Phase 1
1(6.3%)
Phase 3
1(6.3%)
16Total
Phase 2(14)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT06701669Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Role: collaborator

NCT06701682Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Role: collaborator

NCT06703073Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Role: collaborator

NCT06701656Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

Role: collaborator

NCT06555328Phase 2Terminated

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

Role: lead

NCT05964413Phase 3Terminated

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Role: lead

NCT04812535Phase 2Terminated

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Role: lead

NCT03971643Phase 2Completed

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

Role: lead

NCT04333420Phase 2Completed

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

Role: lead

NCT03895801Phase 2Completed

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

Role: lead

NCT03712345Phase 2Terminated

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

Role: lead

NCT03487276Phase 2Completed

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Role: lead

NCT03001622Phase 2Completed

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

Role: lead

NCT02866825Phase 2Completed

Studying Complement Inhibition in Complex Cardiac Surgery

Role: lead

NCT02246595Phase 2Completed

Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction

Role: lead

NCT01319903Phase 1Completed

Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

Role: lead

All 16 trials loaded